View Older Stories

Jan 30, 2026 04:32PM Medicus Pharma (MDCX) files for 4.02M share offering by selling stockholders

Jan 23, 2026 07:30AM Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony

Jan 22, 2026 07:30AM Medicus Pharma amends LifeArc license, cuts Teverelix royalty to 2%

Jan 12, 2026 07:31AM Medicus Pharma study shows stable bone turnover with hormone suppression

Dec 30, 2025 09:29AM Medicus Pharma establishes $15.3 million at-the-market equity program

Dec 30, 2025 06:07AM Medicus Pharma (MDCX) files $100M mixed shelf

Dec 22, 2025 07:31AM Medicus Pharma signs non-binding AI analytics deal with Reliant AI

Dec 22, 2025 07:30AM Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform

Dec 5, 2025 03:26PM Medicus Pharma enters $5.1 million warrant inducement agreement

Dec 5, 2025 03:20PM Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

Dec 1, 2025 08:00AM Medicus Pharma names Carolyn Bonner CFO alongside president role

Dec 1, 2025 08:00AM Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

Nov 17, 2025 07:31AM Medicus Pharma files for FDA priority voucher for skin cancer treatment

Nov 17, 2025 07:30AM Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Nov 14, 2025 05:00PM Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

Nov 13, 2025 07:31AM Medicus Pharma receives UK approvals to expand BCC skin cancer trial

Nov 13, 2025 07:30AM Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Nov 10, 2025 09:00AM BTV Spotlights: Netcoins, Kodiak, Sitka, Kneat, Highland Copper, Northstar Clean Technologies, Mineros, Stillwater, Medicus, & Newcore

Oct 29, 2025 07:30AM Medicus Pharma partners with Gorlin Syndrome Alliance for rare disease access

Oct 29, 2025 07:30AM Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome

Oct 22, 2025 07:30AM Medicus Pharma begins UAE trial for skin cancer treatment

Oct 22, 2025 07:30AM Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Oct 14, 2025 08:07AM The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets

Oct 13, 2025 07:30AM Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025

Oct 7, 2025 07:30AM Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE

Sep 29, 2025 05:06PM Medicus Pharma (MDCX) files for 7.5M share offering by selling stockholders

Sep 29, 2025 07:32AM Medicus Pharma gets FDA backing for basal cell carcinoma treatment path

Sep 29, 2025 07:30AM Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject

Sep 24, 2025 09:26AM Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)

Sep 24, 2025 07:30AM Medicus Pharma Ltd. To Present at Brookline Capital Markets

Sep 18, 2025 07:30AM Medicus Pharma secures $8 million debenture financing for drug development

Sep 18, 2025 07:30AM Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing

Sep 8, 2025 07:31AM Medicus Pharma begins patient recruitment for UAE skin cancer trial

Sep 8, 2025 07:30AM Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Sep 2, 2025 07:32AM Medicus Pharma completes $2.97 million acquisition of Antev Limited

Sep 2, 2025 07:30AM Medicus Pharma Ltd. Completes Acquisition of Antev Limited

Aug 21, 2025 07:42AM Medicus Pharma receives FDA meeting acceptance for basal cell carcinoma drug

Aug 21, 2025 07:30AM Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Secon

Aug 4, 2025 07:32AM Medicus Pharma signs MOU with HelixNano for vaccine development

Aug 4, 2025 07:30AM Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines

Jul 23, 2025 07:30AM Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders

Jul 21, 2025 07:30AM Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025

Jul 8, 2025 07:30AM Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)

Jun 30, 2025 07:32AM Medicus Pharma (MDCX) to Acquire Antev in Share Exchange Deal

Jun 30, 2025 07:30AM Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK

Jun 23, 2025 07:32AM Medicus Pharma (MDCX) Announces Appointment of Andrew Smith as Chief Operating Officer

Jun 23, 2025 07:30AM Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer

Jun 12, 2025 07:30AM Medicus Pharma Ltd. to Present at 2025 Bio International Convention

Jun 9, 2025 07:32AM Medicus Pharma (MDCX) Submits Product Development Plan to the FDA to Treat External Squamous Cell Carcinoma in Horses

Jun 9, 2025 07:30AM Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses

View Older Stories